Dr. Bonomi Discusses PD-L1 as a Biomarker in NSCLC

Philip D. Bonomi, MD
Published: Friday, Oct 06, 2017



Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses PD-L1 as a biomarker in non–small cell lung cancer (NSCLC).

Although PD-L1 is not a perfect biomarker, it remains a player in the immunotherapy arena, says Bonomi.

If regimens like combining immunotherapy and chemotherapy demonstrate good results, there may not even be a need for biomarkers, Bonomi adds.
 


Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses PD-L1 as a biomarker in non–small cell lung cancer (NSCLC).

Although PD-L1 is not a perfect biomarker, it remains a player in the immunotherapy arena, says Bonomi.

If regimens like combining immunotherapy and chemotherapy demonstrate good results, there may not even be a need for biomarkers, Bonomi adds.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x